Purpose: Numerous microRNAs (miRNAs) are aberrantly expressed in breast cancer, and the dysregulation of miRNAs may affect the aggressiveness of this cancer. Aberrant expression of miRNA-937 (miR-937) in gastric and lung cancers has been reported, which plays tumor-suppressive or oncogenic roles in carcinogenesis including cancer progression. Our purpose was to investigate the involvement of miR-937 in breast cancer progression. Patients and methods: The expression profile of miR-937 in breast cancer was assessed by reverse-transcription quantitative PCR. Biological effects of miR-937 upregulation on the malignant characteristics of breast cancer cells were determined in a series of functional experiments. The direct target of miR-937 in breast cancer cells was also identified. Results: Herein, the expression levels of miR-937 were notably lower in breast cancer, and its underexpression was significantly correlated with lymph node metastasis and TNM stage. Patients with breast cancer underexpressing miR-937 showed shorter overall survival than did patients with breast cancer overexpressing miR-937. Proliferation, migration, and invasiveness of breast cancer cells were evidently suppressed by miR-937 upregulation. In addition, ectopic miR-937 expression hindered breast cancer tumor growth in vivo. Forkhead box Q1 (FOXQ1) mRNA was found to be a direct target of miR-937 in breast cancer. FOXQ1 turned out to be overexpressed in breast cancer tissues, and its overexpression negatively correlated with miR-937 expression. Moreover, silencing of FOXQ1 recapitulated the tumor-suppressive effects of miR-937 overexpression on breast cancer cells. Notably, FOXQ1 restoration abrogated the miR-937-mediated suppression of proliferation, migration, and invasiveness of breast cancer cells. Conclusion: These results collectively revealed that miR-937 acts as a tumor suppressor in breast cancer and restrains cancer progression by directly targeting FOXQ1 mRNA. These data suggest that targeting of the novel miR-937-FOXQ1 axis is an attractive therapeutic method against breast cancer.
Introduction
Breast cancer, a highly heterogeneous disease, is the most commonly diagnosed type of malignant tumor and the top cause of cancer-related mortalities among females worldwide. 1 Currently, surgical resection in combination with hormonal including the lifestyle, environment, heredity, and reproductive parameters, are linked to the initiation and progression of breast cancer; [4] [5] [6] however, detailed mechanisms are not completely clarified. Hence, an improved understanding of the pathogenesis of breast cancer may be useful for the identification of promising therapeutic approaches and for improvement of the clinical outcomes of breast cancer.
MicroRNAs (miRNAs) are a group of noncoding single-stranded short RNA molecules consisting of 19-25 nucleotides and serve as powerful regulators of gene expression. 7 An miRNA can recognize and directly bind to a complementary site(s) in the 3′-UTR of a target mRNA, resulting in transcription suppression and/or degradation of the targeted mRNA. 8 In recent years, considerable evidence uncovered the involvement of miRNAs in a wide array of biological events, eg, tumorigenesis including tumor progression. [9] [10] [11] MiRNAs differentially expressed in almost all types of human malignant tumors have been widely reported, including breast cancer. [12] [13] [14] For instance, miR-433, 15 miR-577, 16 and miR-644 are clearly downregulated in breast cancer and play tumorsuppressive roles in the cancer initiation and progression, whereas miR-96, 17 miR-372, 18 and miR-1246 19 are overexpressed in breast cancer and promote cancer progression. Thus, restoration of expression of tumor-suppressive miRNAs and silencing of oncogenic miRNAs may yield high therapeutic efficacy and might be promising anticancer strategies for patients with breast cancer. Aberrant expression of miR-937 has been discovered in gastric 20 and lung 21 cancers and has a tumor-suppressive or oncogenic function. Nevertheless, whether miR-937 contributes to the progression of breast cancer remains poorly understood. In this study, we examined miR-937 expression in breast cancer tissues and cell lines. In vitro and in vivo functional assays were employed to evaluate the detailed effects of forced miR-937 upregulation in breast cancer. Notably, the mechanisms underlying the tumor-suppressive actions of miR-937 on breast cancer progression were investigated in this study.
Materials and methods

Human tissue samples
In total, breast cancer tissue samples and corresponding normal adjacent tissue (NAT) samples were collected from 47 patients who underwent surgical resection in the Weihai Central Hospital. NATs were obtained 2 cm away from breast cancer tissues. Patients who received radiotherapy or chemotherapy were excluded from the study. After the resection, all tissue specimens were snap-frozen in liquid nitrogen and then stored at −80°C. The Ethics Committee of Weihai Central Hospital approved this study. The study was performed in accordance with the Declaration of Helsinki, and written informed consent was provided by all the participants. 
Cell culture conditions
Transfection assays
Cells were seeded in 6-well plates 24 hrs before transfection. To restore miR-937 expression, agomir-937 (Shanghai GenePharma Co., Ltd; Shanghai, China) was transfected into the cells, with agomir-NC as a control in a separate group of cells. Small interfering (si)RNA targeting FOXQ1 mRNA (si-FOXQ1; Guangzhou RiboBio Co., Ltd; Guangzhou, China) was applied to knock down endogenous FOXQ1 expression. Negative control siRNA (si-NC) served as the control for the si-FOXQ1 transfection. FOXQ1 overexpression plasmid pcDNA3. A luciferase reporter assay 
Western blot analysis
The isolation of total protein was carried out with the ProteoPrep ® Total Extraction Sample Kit (SigmaAldrich; EMD Millipore, Billerica, MA, USA). The concentration of total protein was quantified via the Bicinchoninic Acid Protein Assay Kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of protein were loaded and separated by SDS-PAGE in a 10% gel and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). Prior to incubation with primary antibodies overnight at 4°C, the membranes were blocked with 5% skimmed milk in Tris-buffered saline containing 0.1% of Tween 20 (TBST) at room temperature for 2 hrs. After three washes with TBST, a goat anti-rabbit IgG antibody (1:5,000 dilution; horseradish peroxidase-conjugated secondary antibody; cat. # ab6721; Abcam, Cambridge, UK) was incubated with the membranes at room temperature for 1 hr. Finally, the bands were detected using the Enhanced Chemiluminescence Detection Reagent (Pierce Biotechnology, Inc., Rockford, IL, USA). Rabbit anti-human FOXQ1 (ab51340) and anti-human GAPDH (ab181602) antibodies were purchased from Abcam and employed at 1:1,000 dilution.
Statistical analysis
All data from at least three independent experiments were expressed as the mean ± SD. The association between miR-937 and the clinical features of the patients with breast cancer was examined by the χ 2 test. Spearman's correlation analysis was applied to determine the expression correlation between miR-937 and FOXQ1 mRNA in breast cancer tissue samples. The comparison of means between groups was carried out by two-tailed Student's t-test and one-way analysis of variance followed by Tukey's post hoc test. The overall survival rates were calculated by the KaplanMeier method and analyzed using a log-rank test. Statistical Package for Social Sciences version 19.0 (IBM SPSS, Inc., Armonk, NY, USA) was used for all statistical analyses. Data with P<0.05 were considered statistically significant.
Results
miR-937 expression is low in breast cancer
To investigate the expression profile of miR-937 in breast cancer, its expression in 47 pairs of breast cancer tissue samples and NAT samples was measured via RT-qPCR. The expression level of miR-937 was MiR-937 underexpression is correlated with a poor prognosis of patients with breast cancer
To assess the clinical value of miR-937 in breast cancer, all our patients with breast cancer were distributed between a miR-937-low-expression group (n=24) and miR-937-high-expression group (n=23) based on the median value of miR-937 expression in breast cancer tissues.
First, we examined the association between the miR-937 level and clinical parameters in patients with breast cancer. Low miR-937 expression obviously correlated with lymph node metastasis (P=0.008) and TNM stage (P=0.003) among the patients with breast cancer (Table 1) . Notably, patients with breast cancer underexpressing miR-937 showed shorter overall survival than did the patients with breast cancer overexpressing miR-937 ( Figure 1C , P=0.006). These observations indicated that downregulation of miR-937 may be closely linked with the poor prognosis of patients with breast cancer.
miR-937 inhibits the proliferation, migration, and invasiveness of breast cancer cells in vitro
MiR-937 was found to be underexpressed in breast cancer; therefore, we hypothesized that miR-937 may serve as a tumor-suppressive miRNA during breast 
FOXQ1 mRNA is the direct target of miR-937 in breast cancer
It is widely accepted that miRNAs regulate the biological processes associated with cancer by targeting relevant mRNAs. 8 Hence, bioinformatics analysis was conducted to search for the putative target of miR-937 and elucidate the mechanism underlying the suppressive influence of miR-937 on breast cancer progression. As shown in Figure 3A , a putative 7-mer binding site for miR-937 was found in the 3′-UTR of FOXQ1. important functions in the initiation and progression of breast cancer. [23] [24] [25] [26] To evaluate this hypothesis, the luciferase reporter assay was performed to illustrate whether FOXQ1 mRNA is the exact target of miR-937 in breast cancer cells. Resumption of miR-937 expression notably decreased the luciferase activity yielded by the plasmid carrying the WT miR-937-binding site (P<0.05); however, mutation of the miR-937-binding site abrogated the inhibitory effect of miR-937 on the luciferase activity in MDA-MB-231 and MCF-7 cells ( Figure 3B ). Furthermore, ectopic expression of miR-937 notably decreased FOXQ1 expression in MDA-MB-231 and MCF-7 cells at mRNA ( Figure  3C , P<0.05) and protein ( Figure 3D , P<0.05) levels, as evidenced by RT-qPCR and Western blot analyses. Thus, FOXQ1 mRNA is the direct target of miR-937 in breast cancer.
miR-937 is inversely correlated with the expression level of FOXQ1 in breast cancer P<0.05), and invasiveness ( Figure 6D , P<0.05) of MDA-MB-231 and MCF-7 cells were attenuated as well when FOXQ1 expression was restored ectopically. These results suggested that the suppressive effects of miR-937 on the malignancy of breast cancer were at least partly mediated by the downregulation of FOXQ1.
miR-937 inhibits tumor growth in vivo
To better examine the influence of miR-937 on the in vivo growth of breast cancer, MCF-7 cells transfected with agomir-937 or agomir-NC were implanted into nude mice. Consistently with the results observed in vitro, the xenografts derived from the agomir-937-transfected cell group had a smaller tumor volume ( Figure  7A and B, P<0.05) and weight ( Figure 7C , P<0.05) as compared with those in the agomir-NC group of nude mice. Next, miR-937 expression in the xenografts was determined by RT-qPCR. The expression level of miR-937 was notably higher in the agomir-937-transfected group than in the agomir-NC-transfected group ( Figure  7D, P<0.05) . Meanwhile, Western blot analysis was carried out to measure FOXQ1 protein expression in the tumor xenografts. This expression was lower in the agomir-937 group ( Figure 7E, P<0.05) . Collectively, these observations illustrated that miR-937 can effectively inhibit the tumor growth of breast cancer cells in vivo.
Discussion
Numerous miRNAs are differentially expressed in breast cancer, and their expression alterations may affect the initiation and progression of breast cancer. [27] [28] [29] Hence, a comprehensive understanding of the detailed roles of miRNAs in breast cancer might facilitate the identification of novel targets for the treatment of this malignant tumor. In this study, we measured miR-937 expression in breast cancer tissues and cell lines. In addition, the clinical significance of miR-937 in patients with breast cancer was examined. Furthermore, we investigated the biological influence of miR-937 overexpression on breast cancer progression and explored the mechanisms underlying the tumor-suppressive activity of miR-937 in breast cancer cells in vitro and in vivo. MiR-937 is downregulated in gastric cancer tissues and cell lines. 20 On the contrary, miR-937 expression is high in lung cancer. 21 These inconsistent observations prompted us to evaluate the expression pattern of miR-937 in breast cancer. Herein, the results revealed that miR-937 expression is low in breast cancer tissues and cell lines. The low miR-937 expression was obviously correlated with lymph node metastasis and TNM stage among the patients with breast cancer. Patients with breast cancer underexpressing miR-937 showed shorter overall survival than did the patients with breast cancer overexpressing miR-937. These findings suggest that miR-937 may be a diagnostic and/or prognostic biomarker of breast cancer. MiR-937 has been identified as a tumor suppressor in gastric cancer. 20 In particular, resumption of miR-937 expression suppressed gastric cancer cell viability, colony formation, migration, and invasion but induced apoptosis in vitro. 20 In addition, miR-937 overexpression impaired epithelialmesenchymal transition of gastric cancer cells. 20 On the contrary, miR-937 plays an oncogenic part in the progression of lung cancer by promoting anchorage-dependent and -independent growth. 21 Nonetheless, the specific roles of miR-937 in breast cancer have remained largely unclear. In this study, miR-937 was found to have a tumor-suppressive effect on the malignant characteristics of breast cancer, ie, to inhibit breast cancer cell proliferation, migration, and invasion in vitro and tumor growth in vivo. These findings suggest that miR-937 is a promising therapeutic target in breast cancer. is upregulated in breast cancer too and is strongly implicated in the aggressive behaviors of breast cancer cells by participating in cellular regulatory processes, including tumor cell initiation, proliferation, epithelial-mesenchymal transition, and metastasis. [23] [24] [25] [26] Our current study revealed that miR-937-retarded breast cancer progression in vitro and in vivo, and these inhibitory activities were mediated by downregulation of FOXQ1. These findings suggest that resumption of miR-937 expression, which results in FOXQ1 silencing, might be a promising therapeutic method for the management of breast cancer.
Conclusion
MiR-937 expression was found to be low in breast cancer, and this underexpression is closely related to a poor prognosis. MiR-937 plays a tumor-suppressive part in the malignant progression of breast cancer by directly targeting FOXQ1 mRNA, thereby downregulating FOXQ1. These observations provide novel insight into the breast cancer pathogenesis, prompting us to identify effective therapeutic targets in breast cancer in the near future. 
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Ethics approval and informed consent
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